Daily GLP-1 medication news, metabolic health science, and obesity medicine updates — every story sourced, dated and linked. https://metabolicwire.com/ 2026-08-13T12:00:00.000Z https://metabolicwire.com/article/2026-08-13-popular-glp-1-weight-loss-drugs-linked-to-30-lower-breast-cancer-risk 2026-08-13T12:00:00.000Z 2026-08-13T12:00:00.000Z University of Pennsylvania School of Medicine

Penn Medicine research suggests people taking GLP-1 medications such as semaglutide had roughly a 30% lower likelihood of developing breast cancer. (SciTechDaily)

https://metabolicwire.com/article/2026-08-12-eli-lilly-files-first-lawsuits-over-retatrutide-black-market 2026-08-12T12:00:00.000Z 2026-08-12T12:00:00.000Z Shelby Livingston

Eli Lilly sued six US companies for allegedly selling unauthorised copies of retatrutide, its investigational obesity and diabetes drug, ahead of any FDA approval. (Endpoints News)

https://metabolicwire.com/article/2026-08-12-do-glp-1s-belong-in-dermatology-evidence-suggests-a-growing-role 2026-08-12T12:00:00.000Z 2026-08-12T12:00:00.000Z Gabrielle M. Grasso

A review of the evidence that obesity-driven inflammation fuels certain skin diseases, and whether GLP-1 receptor agonists have a therapeutic role in dermatology. (Healio)

https://metabolicwire.com/article/2026-08-11-a-hybrid-lifestyle-program-and-metabolic-health-in-adults-with-obesity 2026-08-11T12:00:00.000Z 2026-08-11T12:00:00.000Z Staff

A Brazilian randomised trial found a hybrid-format lifestyle programme did not significantly improve the odds of achieving 5% weight loss. (JAMA Network Open)

https://metabolicwire.com/article/2026-08-10-new-study-may-change-how-we-think-about-glp-1s 2026-08-10T12:00:00.000Z 2026-08-10T12:00:00.000Z Staff

Yale researchers identified an unexpected brain mechanism behind GLP-1 drugs' effects, challenging long-held assumptions about how they work. (Yale News)

https://metabolicwire.com/article/2026-08-10-uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-di 2026-08-10T12:00:00.000Z 2026-08-10T12:00:00.000Z Staff

The MHRA became the first European regulator to authorise Eli Lilly's orforglipron pill, branded Foundayo, for obesity and diabetes. (GOV.UK (MHRA))

https://metabolicwire.com/article/2026-08-10-uk-approves-its-second-weight-loss-pill-while-eu-access-lags 2026-08-10T12:00:00.000Z 2026-08-10T12:00:00.000Z Helen Collis

Britain cleared Lilly's Foundayo weight-loss pill while a broader EU approval decision remains roughly a year away. (POLITICO)

https://metabolicwire.com/article/2026-08-07-the-oral-glp-1-tracker-lilly-s-foundayo-builds-scripts-after-disappointing-q2 2026-08-07T12:00:00.000Z 2026-08-07T12:00:00.000Z Angus Liu

FiercePharma tracks how Lilly's oral obesity pill Foundayo is gaining prescriptions against Novo Nordisk's Wegovy pill. (FiercePharma)

https://metabolicwire.com/article/2026-08-06-the-divide-between-eli-lilly-and-novo-nordisk-is-widening-after-their-latest-ear 2026-08-06T12:00:00.000Z 2026-08-06T12:00:00.000Z Annika Kim Constantino

Investors cheered Lilly's earnings while punishing Novo's, underscoring a widening confidence gap between the obesity drug rivals. (CNBC)

https://metabolicwire.com/article/2026-08-05-eli-lilly-easily-tops-quarterly-estimates-raises-outlook-as-zepbound-and-mounjar 2026-08-05T12:00:00.000Z 2026-08-05T12:00:00.000Z Annika Kim Constantino

Eli Lilly beat estimates and raised its 2026 revenue outlook to $85–87 billion on surging Zepbound and Mounjaro demand. (CNBC)

https://metabolicwire.com/article/2026-08-05-novo-nordisk-ceo-defends-economics-of-wegovy-pill-as-lower-prices-weigh-on-sales 2026-08-05T12:00:00.000Z 2026-08-05T12:00:00.000Z Staff

Novo Nordisk's chief executive defended the profitability of its discounted Wegovy pill even as pricing pressure hit sentiment. (CNBC)

https://metabolicwire.com/article/2026-08-05-glp-1-drugs-may-reshape-not-replace-bariatric-surgery 2026-08-05T12:00:00.000Z 2026-08-05T12:00:00.000Z Astrid Rivera

Surgeons and endocrinologists discuss how GLP-1 medications are changing, but not eliminating, the role of bariatric surgery. (Medscape)

https://metabolicwire.com/article/2026-08-04-novo-nordisk-shares-slide-after-guidance-disappoints-investors 2026-08-04T12:00:00.000Z 2026-08-04T12:00:00.000Z Staff

Novo Nordisk's U.S.-traded shares dropped about 6% after raised guidance still fell short of Wall Street expectations. (CNBC)

https://metabolicwire.com/article/2026-08-01-analysis-of-19-trials-finds-glp-1-results-differ-by-drug-and-dose-pointing-towar 2026-08-01T12:00:00.000Z 2026-08-01T12:00:00.000Z Staff

A meta-analysis of 19 trials found cardiometabolic outcomes vary meaningfully by GLP-1 drug and dose, favouring personalised treatment. (Medical Daily)

https://metabolicwire.com/article/2026-07-30-lilly-s-obesity-pill-foundayo-gains-early-blockbuster-forecast-as-analysts-float 2026-07-30T12:00:00.000Z 2026-07-30T12:00:00.000Z Staff

Analysts project Lilly's newly approved obesity pill Foundayo could top five million prescriptions in 2026. (FiercePharma)

https://metabolicwire.com/article/2026-07-28-novo-lilly-tout-respective-early-response-and-weight-loss-maintenance-data-as-gl 2026-07-28T12:00:00.000Z 2026-07-28T12:00:00.000Z Staff

Novo Nordisk and Eli Lilly released duelling data on weight-loss maintenance and treatment response as their incretin rivalry deepened. (FiercePharma)

https://metabolicwire.com/article/2026-07-24-tga-issues-warning-over-glp-1-based-drugs-potential-to-cause-rare-eye-disorder 2026-07-24T12:00:00.000Z 2026-07-24T12:00:00.000Z Paige Cockburn

Australia's medicines regulator warned that GLP-1 drugs including Ozempic and Wegovy may be linked to a rare vision-loss condition. (ABC News (Australia))

https://metabolicwire.com/article/2026-07-24-novo-s-ozempic-copy-15-cheaper-but-discovery-still-won-t-change-its-position 2026-07-24T12:00:00.000Z 2026-07-24T12:00:00.000Z Tamar Kahn

Novo Nordisk cut its generic semaglutide price 15% in South Africa, but a major medical scheme called the discount insufficient. (Business Day)

https://metabolicwire.com/article/2026-07-23-lilly-s-triple-agonist-heads-to-regulators-after-two-more-phase-3-obesity-wins 2026-07-23T12:00:00.000Z 2026-07-23T12:00:00.000Z Elizabeth Cairns

Retatrutide, the triple agonist showing the strongest late-stage weight loss to date, is headed for regulatory filing. (Endpoints News)

https://metabolicwire.com/article/2026-07-22-availability-of-generic-semaglutide-removes-barrier-to-affordable-diabetes-care- 2026-07-22T12:00:00.000Z 2026-07-22T12:00:00.000Z Staff

A Canadian economic analysis predicts generic semaglutide will substantially improve access to affordable diabetes care. (Medical Xpress)

https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-drug-ads-it-calls-deceptive 2026-07-21T12:00:00.000Z 2026-07-21T12:00:00.000Z Ed Silverman

Novo Nordisk sued Eli Lilly in New Jersey federal court, alleging its rival's ads use outdated trial data to overstate efficacy. (STAT News)

https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-ads 2026-07-21T12:00:00.000Z 2026-07-21T12:00:00.000Z Annika Kim Constantino

CNBC details Novo Nordisk's false-advertising lawsuit against Eli Lilly over comparative obesity drug efficacy claims. (CNBC)

https://metabolicwire.com/article/2026-07-19-orforglipron-pill-beats-oral-semaglutide-in-major-diabetes-trial 2026-07-19T12:00:00.000Z 2026-07-19T12:00:00.000Z Staff

A Phase 3 trial found orforglipron lowered HbA1c and produced more weight loss than oral semaglutide, with more GI side effects. (Diabetes.co.uk)

https://metabolicwire.com/article/2026-07-15-novo-nordisk-receives-european-commission-approval-of-wegovy-pill-as-first-oral- 2026-07-15T12:00:00.000Z 2026-07-15T12:00:00.000Z Staff

The European Commission approved the Wegovy pill, the first oral GLP-1 authorised for weight management in the EU. (Novo Nordisk)

https://metabolicwire.com/article/2026-07-09-medicare-prescriptions-for-wegovy-spike-after-heart-disease-coverage-expansion 2026-07-09T12:00:00.000Z 2026-07-09T12:00:00.000Z Staff

USC Schaeffer researchers found Medicare Wegovy prescriptions rose sharply after cardiovascular coverage expanded, though uptake remains low. (News-Medical)

https://metabolicwire.com/article/2026-07-01-medicare-is-now-covering-some-glp-1-weight-loss-drugs-for-50-here-s-what-to-know 2026-07-01T12:00:00.000Z 2026-07-01T12:00:00.000Z Ali Swenson

The federal government began offering discounted $50 GLP-1 drugs such as Wegovy and Zepbound to eligible older Americans. (Associated Press)

https://metabolicwire.com/article/2026-06-30-the-loophole-in-trump-s-obesity-drug-deal-with-eli-lilly-and-novo-nordisk 2026-06-30T12:00:00.000Z 2026-06-30T12:00:00.000Z John Wilkerson

The administration's low-cost GLP-1 pricing deal boosted drugmaker volume without delivering the lower prices originally promised. (STAT News)

https://metabolicwire.com/article/2026-06-24-u-s-health-spending-rose-sharply-in-2025-thanks-to-glp-1-use-and-more-care 2026-06-24T12:00:00.000Z 2026-06-24T12:00:00.000Z Bob Herman

National health spending topped $6 trillion, driven in part by surging use of GLP-1 medications. (STAT News)

https://metabolicwire.com/article/2026-06-23-eli-lilly-gave-extraordinary-obesity-drug-access-to-a-79-year-old-patient-who-wa 2026-06-23T12:00:00.000Z 2026-06-23T12:00:00.000Z Lizzy Lawrence

STAT investigates how Eli Lilly granted rare compassionate-use access to its unapproved obesity drug retatrutide. (STAT News)

https://metabolicwire.com/article/2026-06-18-what-s-next-for-glp-1-weight-loss-drugs 2026-06-18T12:00:00.000Z 2026-06-18T12:00:00.000Z Alex Hogan

A status report on the obesity drug market as Pfizer and Amgen race to challenge Novo Nordisk and Eli Lilly's dominance. (STAT News)

https://metabolicwire.com/article/2026-06-15-trump-s-obesity-drug-plan-creates-a-temporary-medicare-program-that-may-be-hard- 2026-06-15T12:00:00.000Z 2026-06-15T12:00:00.000Z John Wilkerson

Medicare will cover weight-loss drugs for seniors for the first time under a temporary bridge programme. (STAT News)

https://metabolicwire.com/article/2026-06-09-ada-lilly-bests-novo-again-takes-glp-1-pill-foundayo-to-fda-for-diabetes-approva 2026-06-09T12:00:00.000Z 2026-06-09T12:00:00.000Z Staff

Foundayo outperformed semaglutide on blood-sugar reduction in Phase 3 diabetes trials, prompting an FDA filing. (BioSpace)

https://metabolicwire.com/article/2026-06-08-astrazeneca-s-glp-1-pill-shows-promise-in-obesity-diabetes-trials 2026-06-08T12:00:00.000Z 2026-06-08T12:00:00.000Z Elaine Chen

AstraZeneca's investigational oral GLP-1 showed promising mid-stage results, though liver-safety questions linger. (STAT News)

https://metabolicwire.com/article/2026-06-08-achieve-trials-demonstrate-comparative-benefits-of-novel-small-molecule-oral-glp 2026-06-08T12:00:00.000Z 2026-06-08T12:00:00.000Z Staff

The first head-to-head trial comparing two oral GLP-1 receptor agonists pointed to expanded treatment options for patients. (American Diabetes Association)

https://metabolicwire.com/article/2026-06-07-ada26-19-of-phase-3-patients-quit-boehringer-obesity-shot-over-side-effects 2026-06-07T12:00:00.000Z 2026-06-07T12:00:00.000Z Elizabeth Cairns

Nearly one in five Phase 3 patients dropped Boehringer and Zealand's obesity injection survodutide because of side effects. (Endpoints News)

https://metabolicwire.com/article/2026-05-29-tirzepatide-raises-thyroid-risk-in-certain-at-risk-patients 2026-05-29T12:00:00.000Z 2026-05-29T12:00:00.000Z Staff

A 12-month study found tirzepatide raised thyroid disorder risk in patients with kidney disease or existing thyroid conditions. (Medscape)

https://metabolicwire.com/article/2026-05-28-cvs-restores-zepbound-coverage-adds-eli-lilly-s-obesity-pill-foundayo 2026-05-28T12:00:00.000Z 2026-05-28T12:00:00.000Z Staff

CVS said it will restore standard-plan coverage of Zepbound and add coverage for Lilly's new obesity pill Foundayo. (CNBC)

https://metabolicwire.com/article/2026-05-21-eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial 2026-05-21T12:00:00.000Z 2026-05-21T12:00:00.000Z Berkeley Lovelace Jr.

Lilly's triple-hormone agonist retatrutide helped patients lose up to 28.3% of body weight in a late-stage trial. (CNBC)

https://metabolicwire.com/article/2026-05-21-lilly-s-triple-agonist-still-leads-among-late-stage-obesity-assets 2026-05-21T12:00:00.000Z 2026-05-21T12:00:00.000Z Elizabeth Cairns

Retatrutide remains the leading late-stage obesity candidate by weight-loss magnitude among current competitors. (Endpoints News)

https://metabolicwire.com/article/2026-05-13-wegovy-pill-delivered-21-6-weight-loss-in-early-responders-and-doubled-mobility- 2026-05-13T12:00:00.000Z 2026-05-13T12:00:00.000Z Staff

The oral Wegovy pill showed 21.6% weight loss in early responders in the OASIS 4 trial presented at ECO2026. (Novo Nordisk)